Literature DB >> 11060355

HDL modification by secretory phospholipase A(2) promotes scavenger receptor class B type I interaction and accelerates HDL catabolism.

F C de Beer1, P M Connell, J Yu, M C de Beer, N R Webb, D R van der Westhuyzen.   

Abstract

During inflammatory states plasma levels of high density lipoprotein (HDL) cholesterol and apolipoprotein A-I (apoA-I) are reduced. Secretory group IIa phospholipase A(2) (sPLA(2)) is a cytokine-induced acute-phase enzyme associated with HDL. Transgenic mice overexpressing sPLA(2) have reduced HDL levels. Studies were performed to define the mechanism for the HDL reduction in these mice. HDL isolated from sPLA(2) transgenic mice have a significantly lower phospholipid content and greater triglyceride content. In autologous clearance studies, (125)I-labeled HDL from sPLA(2) transgenic mice was catabolized significantly faster than HDL from control mice (4.24 +/- 1.16 vs. 2.84 +/- 0.1 pools per day, P < 0.008). In both sPLA(2) transgenic and control mice, the cholesteryl ester component of HDL was more rapidly catabolized than the protein component, indicating a selective uptake mechanism. In vitro studies using CHO cells transfected with scavenger receptor class B type I (SR-BI) showed that sPLA(2)-modified HDL was nearly twice as efficient as a substrate for cholesteryl ester transfer. These data were confirmed in in vivo selective uptake experiments using adenoviral vector overexpression of SR-BI. In these studies, increased hepatic selective uptake was associated with increased (125)I-labeled apolipoprotein uptake in the kidney. We conclude that during inflammation sPLA(2) hydrolysis of HDL phospholipids alters the lipid composition of the particle, allowing for more efficient SR-BI-mediated selective cholesteryl ester uptake. This enhanced SR-BI activity generates HDL remnants that are preferentially catabolized in the kidney.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11060355

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  20 in total

1.  BMI modifies the association between serum HDL cholesterol and stroke in a hypertensive population without atrial fibrillation.

Authors:  Y Yu; L Hu; X Huang; W Zhou; H Bao; X Cheng
Journal:  J Endocrinol Invest       Date:  2020-05-13       Impact factor: 4.256

2.  Inflammation modulates human HDL composition and function in vivo.

Authors:  Margarita de la Llera Moya; Fiona C McGillicuddy; Christine C Hinkle; Michael Byrne; Michelle R Joshi; Vihn Nguyen; Jennifer Tabita-Martinez; Megan L Wolfe; Karen Badellino; Leticia Pruscino; Nehal N Mehta; Bela F Asztalos; Muredach P Reilly
Journal:  Atherosclerosis       Date:  2012-02-28       Impact factor: 5.162

3.  Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice.

Authors:  Roshni Srivastava; Shaohua Yu; Brian W Parks; Leland L Black; Janusz H Kabarowski
Journal:  Arthritis Rheum       Date:  2011-01

4.  Endothelial cell-derived lipase mediates uptake and binding of high-density lipoprotein (HDL) particles and the selective uptake of HDL-associated cholesterol esters independent of its enzymic activity.

Authors:  Juliane G Strauss; Robert Zimmermann; Andelko Hrzenjak; Yonggang Zhou; Dagmar Kratky; Sanja Levak-Frank; Gert M Kostner; Rudolf Zechner; Sasa Frank
Journal:  Biochem J       Date:  2002-11-15       Impact factor: 3.857

5.  Endothelial lipase-modified high-density lipoprotein exhibits diminished ability to mediate SR-BI (scavenger receptor B type I)-dependent free-cholesterol efflux.

Authors:  Martin Gauster; Olga V Oskolkova; Josef Innerlohinger; Otto Glatter; Gabriele Knipping; Sasa Frank
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

Review 6.  Dysfunctional HDL and atherosclerotic cardiovascular disease.

Authors:  Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb
Journal:  Nat Rev Cardiol       Date:  2015-09-01       Impact factor: 32.419

7.  Inflammation impairs reverse cholesterol transport in vivo.

Authors:  Fiona C McGillicuddy; Margarita de la Llera Moya; Christine C Hinkle; Michelle R Joshi; Elise H Chiquoine; Jeffrey T Billheimer; George H Rothblat; Muredach P Reilly
Journal:  Circulation       Date:  2009-02-16       Impact factor: 29.690

8.  Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.

Authors:  Christopher P Sullivan; Stephanie E Seidl; Celeste B Rich; Michel Raymondjean; Barbara M Schreiber
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

9.  Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2).

Authors:  Wijtske Annema; Niels Nijstad; Markus Tölle; Jan Freark de Boer; Ruben V C Buijs; Peter Heeringa; Markus van der Giet; Uwe J F Tietge
Journal:  J Lipid Res       Date:  2010-01-08       Impact factor: 5.922

10.  2H2O-based high-density lipoprotein turnover method for the assessment of dynamic high-density lipoprotein function in mice.

Authors:  Takhar Kasumov; Belinda Willard; Ling Li; Min Li; Heather Conger; Jennifer A Buffa; Stephen Previs; Arthur McCullough; Stanley L Hazen; Jonathan D Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-06-13       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.